This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (403) Obsessive-Compulsive Disorder (OCD) (40)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/39223, first published .
Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial

Authors of this article:

Annalisa Maraone1 Author Orcid Image ;   Alessandro Trebbastoni1 Author Orcid Image ;   Antonella Di Vita1 Author Orcid Image ;   Fabrizia D'Antonio1 Author Orcid Image ;   Carlo De Lena2 Author Orcid Image ;   Massimo Pasquini1 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics

Journals

  1. Mirzazadeh H, Ghaeminia Y, Mohamad Niaei A, Kamran M, Razeghian Jahromi L, Moshfeghinia R. Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial. BMC Psychiatry 2025;25(1) View